Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis

BackgroundOfatumumab, a fully human monoclonal antibody targeting CD20, is approved for the treatment of relapsing multiple sclerosis. Comprehensive real-world safety data are crucial for informing clinical practice.MethodsThe FDA Adverse Event Reporting System database was utilized to perform a dis...

Full description

Saved in:
Bibliographic Details
Main Author: Hui Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1521726/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832590805118746624
author Hui Chen
author_facet Hui Chen
author_sort Hui Chen
collection DOAJ
description BackgroundOfatumumab, a fully human monoclonal antibody targeting CD20, is approved for the treatment of relapsing multiple sclerosis. Comprehensive real-world safety data are crucial for informing clinical practice.MethodsThe FDA Adverse Event Reporting System database was utilized to perform a disproportionality analysis, covering reports from Q3 2020 to Q2 2024, in which ofatumumab was identified as the primary suspected drug. Statistical approaches used included the Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker. The timing of adverse events was assessed using the Weibull distribution model to highlight temporal risk patterns.ResultsKnown adverse reactions, such as injection site reactions and upper respiratory tract infections, displayed positive signals. Additionally, novel off-label adverse events, including brain fog, muscle spasms, and mood alterations, were identified, marking the first real-world evidence of these potential risks. Temporal analysis revealed that most adverse events occurred within the first month of treatment, indicating an early risk phase. Subgroup analysis demonstrated notable differences in adverse event profiles by gender and age, with males more prone to hyperhidrosis and older patients more susceptible to neurological symptoms.ConclusionThis real-world analysis of ofatumumab provides important safety insights, confirming known adverse reactions and identifying additional potential risks. Early and tailored monitoring protocols during the initial treatment phase, including regular neurological and psychiatric assessments, are recommended to optimize patient safety and outcomes. Prospective studies are recommended to validate these results and explore the underlying mechanisms.
format Article
id doaj-art-387432c00a674ce3a6853b0057165cd7
institution Kabale University
issn 1663-9812
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-387432c00a674ce3a6853b0057165cd72025-01-23T06:56:25ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15217261521726Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysisHui ChenBackgroundOfatumumab, a fully human monoclonal antibody targeting CD20, is approved for the treatment of relapsing multiple sclerosis. Comprehensive real-world safety data are crucial for informing clinical practice.MethodsThe FDA Adverse Event Reporting System database was utilized to perform a disproportionality analysis, covering reports from Q3 2020 to Q2 2024, in which ofatumumab was identified as the primary suspected drug. Statistical approaches used included the Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker. The timing of adverse events was assessed using the Weibull distribution model to highlight temporal risk patterns.ResultsKnown adverse reactions, such as injection site reactions and upper respiratory tract infections, displayed positive signals. Additionally, novel off-label adverse events, including brain fog, muscle spasms, and mood alterations, were identified, marking the first real-world evidence of these potential risks. Temporal analysis revealed that most adverse events occurred within the first month of treatment, indicating an early risk phase. Subgroup analysis demonstrated notable differences in adverse event profiles by gender and age, with males more prone to hyperhidrosis and older patients more susceptible to neurological symptoms.ConclusionThis real-world analysis of ofatumumab provides important safety insights, confirming known adverse reactions and identifying additional potential risks. Early and tailored monitoring protocols during the initial treatment phase, including regular neurological and psychiatric assessments, are recommended to optimize patient safety and outcomes. Prospective studies are recommended to validate these results and explore the underlying mechanisms.https://www.frontiersin.org/articles/10.3389/fphar.2024.1521726/fullofatumumabmultiple sclerosispharmacovigilanceFAERS databaseadverse eventsdisproportionality analysis
spellingShingle Hui Chen
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
Frontiers in Pharmacology
ofatumumab
multiple sclerosis
pharmacovigilance
FAERS database
adverse events
disproportionality analysis
title Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
title_full Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
title_fullStr Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
title_full_unstemmed Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
title_short Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
title_sort real world pharmacovigilance of ofatumumab in multiple sclerosis a comprehensive faers data analysis
topic ofatumumab
multiple sclerosis
pharmacovigilance
FAERS database
adverse events
disproportionality analysis
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1521726/full
work_keys_str_mv AT huichen realworldpharmacovigilanceofofatumumabinmultiplesclerosisacomprehensivefaersdataanalysis